Oritinib (mesylate)
Product Specifications
UNSPSC Description
Oritinib (SH-1028) mesylate is a selective, orally active, and pyrimidine-based irreversible inhibitor of EGFR with an IC50 of 18 nM. Oritinib (SH-1028) mesylate exhibits potent activity against EGFR sensitive and resistant (T790 M) mutations. Oritinib (SH-1028) mesylate significantly inhibits proliferation of tumor cells with EGFR sensitive and resistant mutation[1].
Target Antigen
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/oritinib-mesylate.html
Solubility
10 mM in DMSO
Smiles
CS(=O)(O)=O.O=C(NC1=CC(NC2=NC(C3=C(CCCC4)N4C5=C3C=CC=C5)=CC=N2)=C(C=C1N(CCN(C)C)C)OC)C=C
Molecular Weight
635.78
References & Citations
[1]Han L, et al. SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer. Front Pharmacol. 2021;12:665253.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-139920A/Oritinib-mesylate-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-139920A/
Clinical Information
Phase 3
CAS Number
2180164-79-6
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Rat Monoclonal Reg1A Antibody (431202) [DyLight 350]](https://cdn.genprice.uk/genprice/genprice2.png)